Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Crave Hot Dogs and BBQ, a US-based speciality hot dogs and barbecue chain, is expanding its footprint across the US with ...

Operational risks are also reduced due to a lesser need for human intervention in hazardous environments, which is a very ...

It’s become evident that a cloud-based IT portfolio brings organisations the greatest promise for providing the type of ...

In a release sent to Rigzone recently, GlobalData said the oil and gas industry has seen a dip in active jobs in 2024 but ...

KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Virtual reality primarily has applications around training across the oil and gas value chain,' GlobalData said.

AI-driven adaptive cardiac devices are revolutionizing heart disease treatment by enabling real-time monitoring and dynamic ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...